Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
Patent 5447936 Issued on September 5, 1995. Estimated Expiration Date: December 22, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
10-hydroxy 7-ethyl camptothecin (HECPT), an active metabolite of the camptothecin analog CPT-11, is poorly soluble in water. Because of its poor water solubility, HECPT has not been directly administered by parenteral or oral routes in human patients for the purpose of inhibiting the growth of cancer cells. There is also unpredictable interpatient variability in the metabolic production of HECPT from CPT-11 which limits the utility of CPT-11. This invention overcomes these limitations by teaching novel pharmaceutically acceptable lactone stable HECPT formulations for the direct administration of HECPT. The claimed invention also describes novel dosages, schedules, and routes of administration of the lactone stable HECPT formulations to patients with various forms of cancer.
Other References
Akimoto, K., et al., Selective and Sensitive Determination of Lactone and Hydroxy Acid Forms of Camptothecin and Two Derivatives (CPT-11 and SN-38) by High-Performance Liquid Chromatography with Fluorescence Detection. Journal of Chromatography, 588:165-170, 1991
Baer, Ora, Taxotere, Topotecan, and CPT-11: Clinical Trails Confirm Early Promise. Oncology Times, pp. 8-10, May 1993
Barilero et al., Simultaneous Determination of the Camptothecin Analogue CPT-11 and Its Active Metabolite SN-38 by High Performance Liquid Chromatography: Application to Plasma Pharmacokinetic Studies in Cancer Patients. J. Chromat. 575:275-280: 1992
Bates et al., Solubilizing Properties of Bile Salt Solutions I--Effect of Temperature and Bile Salt Concentration on Solubilizattion of Glute-ethimide, Griseofulvin and Hexestrol. Journal of Pharmaceutical Sciences, 55:191-199, 1966
Bates et al., Rates of Dissolution of Griseofulvin and Hexestrol in Bile Salt Solutions. Chem. Abstracts 65:8680b, 1966
Bates et al., Solubilizing Properties of Bile Salt Solutions on Gluteththimide, Griseofulvin, and Hexestrol. Chem. Abstracts 65:9517e, 1966; 65:15165a, 1966
Clavel, M. et al., Phase I Study of the Camptothecin Analogue CPT-11, Administered Daily for 3 Consecutive Days. Proc. Amer. Assoc. Cancer Res. 3:83, 1992
Creavan, P. J., Plasma Camptothecin (NSC 100880) Levels During a 3-Day Course of Treatment: Relation to Dose and Toxicity. Cancer Chemotherapy Rep. 56:573-578, 1972
Culine, S., Phase I Study of the Camptothecin Analogue CPT-11, Using a Weekly Schedule. Proc. of Amer. Soc. Clin. Onc. 11:110, 1992
Eckardt, J. et al., Topoisomerase I Inhibitors: Promising Novel Compounds. Div. of Med. Oncology, U. of Tex. Health Sci., 1993
Fukuoka, M. et al., A Phase II Study of CPT-11, A New Derivative of Camptothecin, for Previously Untreated Non Small-Cell Lung Cancer. J. Clin. Onc. 10(1):16-20, 1992
Giovanella, B. C. et al., DNA Topoisomerase I--Targeted Chemotherapy of Human Colan Cancer in Xenografts. Science 246:1046-1048, 1989
Gottlieb, J. A., Preliminary Pharmacologic and Clinical Evaluation of Camptothecin Sodium (NSC-100880). Cancer Chemotherapy Rep. 54:461-470, 1970
Gottlief, J. A., Treatment of Maglignant Melanoma with Camptothecin (NSC-100880), Cancer Chemotherapy Rep. 57:103-105, 1972
Hsiang et al., Arrest of Replication Forks by Drug-stabilized Topisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin Analogues. Cancer Res. 49:5077-5082, 1989
Jaxel, C. et al., Structure Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topisomerase I: Evidence for a Specific Receptor Site and a Relation to Antitumor Activity. Cancer Res. 49:1465-1469, 1989
Kaneda, N. et al., Metabolism and Pharmacokinetics of the Camptothecin Analogue CPT-11 in the Mouse. Cancer Reserch 50:1715-1720, 1990
Kano Y. et al., Effects of CPT-11 in Combination With Other Anti-Cancer Agents in Culture. Int. J. Cancer 50:604-610, 1992
Kanzawa F. et al., Role of Carboxylesterase on Metabolism of Camptothecin Analog (CPT-11) in Non-Small Cell Lung Cancer Cell Line PC-7 Cells (Meeting Abstract), Proc. Annual Meet. Am. Assoc. Cancer Res. 33:A2552, 1992
Kawato, Y. et al., Intracellular Roles of SN-38, a Metabolite of the Camptothecin Derivative CPT-11, in the Antitumor Effect of CPT-11. Cancer Res. 51:4187-4191, 1991
Kingsbury, W. D. et al., Synthesis of Water-Soluble (Aminoalkyl) Camptothecin Analogues: Inhibition of Topoisomerase I and Antitumor Activity. J. Med. Chem. 34:98-107, 1991
Kunimoto, T. et al., Antitumor Activity of 7-Ethyl-10-[4-(1-Piperidino)-1-piperidino] Carbonyloxy-Camptothecin, a Novel Water Soluble Derivative of Camptothecin Against Murine Tumors. Cancer Res. 47:5944-5947, 1987
Malone et al., Desoxycholic Acid Enhancement of Orally Administered Reserpine. Journal of Pharmaceutical Sciences, 55:972-974, 1966
Masuda, N. et al., CPT-11: A New Derivative of Camptothecin for the Treatment of Refractory or Relapsed Small-Cell Lung Cancer. J. Clin. Onc. 10(8):1225-1229, 1992
Moertel, C. G., Phase II Study of Camptothecin (NSC-100880) in the Treatment of Advanced Gastrointestinal Cancer. Cancer Chemotheraphy Rep. 57:103-105, 1972
Muggia, F. M., Phase I Clinical Trial of Weekly and Daily Treatment with Camptothecin (NSC-100880): Correlation With Preclinical Studies. Cancer Chemotherapy Rep. 55:515-521, 1972
Negoro, S. et al., Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small Cell Lung Cancer. JNCI 83(16): 1164-1168, 1991
Negoro, S. et al., Phase II Study of CPT-11, a New Camptothecin Derivative, in Small Cell Lung Cancer. Proc. of Amer. Soc. Clin. Onc. 10:241, 1991
Niimi S. et al., Mechanism of Cross-Resistance to a Captothecin Analogue (CPT-11) in a Human Ovarian Cancer Cell Line Selected by Cisplatin. Cancer Res. 52:328-333, 1992
Ohe,. Y. et al., Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Coninuous Infusion. JNCI 84(12):972-974, 1992
Ohno, R. et al., An Early Phase II Study of CPT-11: A New Derivative of Camptothecin, for the Treatment of Leukemia and Lymphoma. J. Clin. Onc. 8(11): 1907-1912, 1990
Pommier, Y. et al., Camptothecins: Mechanism of Action and Resistance (Meeting Abstract). Cancer Investigation, Presented at the "Chemotherapy Foundation Symposium X Innovative Cancer Chemotherapy for Tomorrow," p. 3, 1992
Rothenberg, M. L. et al., A Phase I and Pharmacokinetic Trail of CPT-11 in Patients With Refractory Solid Tumors. Amer. Soc. Clin. Onc. 11:113, 1992
Rothenberg, M. L. et al., Phase I and Pharmacokinetic Trial of Weekly CPT-11. Journal of Clinical Oncology. 11:2194-2204, 1993
Rowinsky, E. et al., Phase I and Pharmacologic Study of CPT-11, A Semisythetic Topoisemerase I-Targeting Agent, on a Single Dose Schedule (Meeting Abstract). Proc. of Amer. Soc. Clin. Onc. 11:114, 1992
Sawada, S. et al., Synthesis and Antitumor Activity of 20 (S)--Camptothecin Derivatives: Carbonate-Linked. Water-Soluble, Derivatives of 7-Ethyl-10-Hydroxycamptothecin. Chem. Pharm. Bull. 39:1446-1454, 1991
Shimada, Y. et al., Phase II Study of CPT-11, New Camptothecin Derivative in the Patients with Metastatic Colorectual Cancer. Proc. of Amer. Soc. Clin. Onc. 10:135, 1991
Takeuchi, S. et al., Late Phase II Study of CPT-11, A Topoisomerase I Inhibitor , in Advanced Cerivical Carcinoma (CC) (Meeting Abstract). Proc. of Amer. Soc. Clin. Onc. 11:224, 1992
Wall, M. E. et al. Plant Anti-tumor Agents I--The Isolation and Stucture of Camptothecin, a Novel Alkaloidal Leulemia and Tumor Inhibitor from Camptotheca Acuminata. J. Amer. Chem. Soc. 88:3888-90, 1966
Westergaard et al., The Mechanism Whereby Bile Acid Mycelles Increase the Rate of Fatty Acid and Cholesterol Uptake Into the Intestinal Mucosal Cell. Journal of Clinical Investigation, 58:97-108 (1976)
Kawato, Y., et al., Antitumor Activity of a Camptothecin Derivative, CPT-11, Against Human Tumor Xenografts in Nude Mice. Cancer Chemother Pharmacol, 28:192-198, 1991
Ejima, A., et al., Antitumor Agents V.1) Synthesis and Antileukemic Activity of E-Ring-Modified (RS)-Camptothecin Analogues. Chem. Pharm. Bull., 40(3):683-688, Mar., 1992
Pommier, Y., et al., Chapter 9: Mammalian DNA Topoisomerase I and Its Inhibitors. In: Cancer Chemotherapy, Eds. Hickman and Tritton, Publisher: Blackwell Scientific Publications, pp. 214-250, 1993
Extra, J. M., et al., Phase 1 Study of CPT-11, A Camptothecin Analogue, Administered as a Weekly Infusion. Proc. Amer. Assoc. Cancer Res., 3:83, 1992
Rowinsky, E., et al., Phase I and Pharmacologic Studies of Topotecan, A Novel Topoisomerase I Inhibitor Without and With G-CSF. Proc. Amer. Assoc. Cancer Res., 3:83, 1992
Kuhn, J., et al., Pharmacokinetcis of Topotecan Following a 30 Min Infusion or 3 Day Continuous Infusion. Proc. Amer. Assoc. Cancer Res., 3:83, 1992
Pantazis, P., et al., Cytotoxic Efficacy of 9-Nitrocamptothecin in the Treatment of Human Malignant Melanoma Cells in Vitrol. Cancer Research, 54:771-776, Feb., 1994
Rowinsky, E. K., et al., Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weels1. Cancer Research, 54:427-436, Jan., 1994
Nicholas, A. W., et al., Plant Antitumor Agents. 29.1 Synthesis and Biological Activity of Ring D and Ring E Modified Analogues of Camptothecin. J. Med. Chem. 33:978-985, 1990
Potmesil, Milan, et al., Camptothecins: From Bench Research to Hospital Wards. Cancer Research 54:1431-1439, Mar. 1994
December 22, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
